# Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

> **NCT01775930** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT01775930
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2019-01-18
- **Final completion:** 2019-01-18
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01775930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01775930, "Carfilzomib in Refractory Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01775930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*